Arrowhead Pharmaceuticals receives reaffirmed "buy" rating at $60 target price from Chardan Capital.

Arrowhead Pharmaceuticals' (ARWR) "buy" rating is reaffirmed at Chardan Capital with a $60 target price, indicating a potential upside of 172.48% from the stock's previous close. Recent reports from other analysts include Royal Bank of Canada's "outperform" rating and $50 price objective, HC Wainwright's "buy" rating and $90 price objective, and Citigroup's "neutral" rating with a $34 price objective.

May 10, 2024
4 Articles